Interpreting discordant indirect and multiple treatment comparison meta-analyses: An evaluation of direct acting antivirals for chronic hepatitis C infection

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 173-183

  Druyts, Eric ^a   Thorlund, Kristian ^b,c   Humphreys, Samantha ^d   Lion, Michaela ^d   Cooper, Curtis L ^e   Mills, Edward J ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Merck Sharp & Dohme Limited   (United Kingdom)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Hepatitis c virus; Indirect treatment comparison; Meta analysis; Multiple treatment comparison

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ARTICLE; COMPARATIVE EFFECTIVENESS; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HUMAN; INDIRECT TREATMENT COMPARISON META ANALYSIS; META ANALYSIS (TOPIC); METHODOLOGY; MULTIPLE TREATMENT COMPARISON META ANALYSIS; PATIENT ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAMPLING; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84879283557     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S44273     Document Type: Article

References (31)

1. Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-691.
2. Sutton A, Ades A, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26(9):753-767.
3. Wells G, Sultan S, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons In Meta-Analysis. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health; 2009.
4. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64(11):1187-1197.
5. Hoaglin D, Hawkins N, Jansen J, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429-437.
6. Jansen J, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14(4):417-428.
7. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011. Available from: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%20Mar2013.pdf. Accessed February 12, 2013.
8. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
9. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124.
10. Thorlund K, Druyts E, Avina-Zubieta J, Wu P, Mills E. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis. Epub October 20, 2012.
11. Jadad A, Cook D, Browman G. A guide to interpreting discordant systematic reviews. Can Med Assoc J. 1997;156(10):1411-1416.
12. McHutchison J, Everson G, Gordon S, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
13. Hezode C, Forestier N, Dusheiko G, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.
14. Jacobson I, McHutchison J, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
15. McHutchison J, Manns M, Muir A, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-1303.
16. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364: 2417-2428.
17. Kwo P, Lawitz E, McCone J, et al; SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716.
18. Poordad F, McCone J, Bacon B, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
19. Bacon B, Gordon S, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
20. Flamm S, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013;11(1):81-87.
21. Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM. 2013;106(2):153-163.
22. Cooper C, Druyts E, Thorlund K, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8: 105-130.
23. Cure S, Diels J, Gavart S, Bianic F, Jones E. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin. 2012;28(11): 1841-1856.
24. Kieran J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clininical Infectious Diseases. Jan 2013;56(2):228-235.
25. McHutchison J, Lawitz E, Shiffman M, et al; IDEAL Study team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
26. Druyts E, Mills E, Nachega J, O'Regan C, Cooper C. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol. 2012;5:11-21.
27. Higgins JPT, Green S, editors. The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: http://www.cochranehandbook.org.Accessed May 6, 2013.
28. Eisenberg M, Filion K, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(2):135-144.
29. Mills E, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert J. Comparisons of high dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(4):588-597.
30. Mills E, Wu P, Spurden D, Ebbert J, Wilson K. Eff icacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J. 2009;6:25.
31. Walter S. Choice of effect measure for epidemiological data. J Clinical Epidemiol. 2000;53(9):931-939.